GLPG Galapagos NV Stock Quote

GLPG [NASD]

Index	-	P/E	-	EPS (ttm)	-3.06	Insider Own	-	Shs Outstand	65.55M	Perf Week	0.42%
Market Cap	3.80B	Forward P/E	-	EPS next Y	-3.25	Insider Trans	-	Shs Float	40.05M	Perf Month	-10.61%
Income	-	PEG	-	EPS next Q	-0.88	Inst Own	16.22%	Short Float	1.59%	Perf Quarter	-13.19%
Sales	526.20M	P/S	7.22	EPS this Y	45.70%	Inst Trans	-	Short Ratio	1.95	Perf Half Y	9.81%
Book/sh	39.94	P/B	1.45	EPS next Y	-5.90%	ROA	-	Target Price	73.67	Perf Year	-22.60%
Cash/sh	-	P/C	-	EPS next 5Y	0.71%	ROE	-	52W Range	46.41 - 81.12	Perf YTD	5.15%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-28.54%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	24.91%	ATR	2.08
Employees	1319	Current Ratio	-	Sales Q/Q	-49.70%	Oper. Margin	-	RSI (14)	41.42	Volatility	2.72% 3.20%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	1.73	Prev Close	58.83
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	325.69K	Price	57.97
Recom	2.60	SMA20	-4.10%	SMA50	-7.28%	SMA200	0.34%	Volume	563,593	Change	-1.46%

Jan-27-22

Upgrade

Citigroup

Neutral → Buy

Aug-19-21

Downgrade

Barclays

Overweight → Equal Weight

Aug-06-21

Downgrade

Deutsche Bank

Buy → Hold

Apr-20-21

Initiated

Deutsche Bank

Buy

Apr-14-21

Upgrade

Barclays

Equal Weight → Overweight

Feb-23-21

Upgrade

BofA Securities

Underperform → Neutral

$93 → $94

Feb-19-21

Upgrade

Raymond James

Mkt Perform → Outperform

Feb-11-21

Downgrade

Citigroup

Buy → Neutral

Jan-19-21

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$159 → $129

Nov-19-20

Initiated

Maxim Group

Buy

$170

Oct-21-20

Downgrade

Goldman

Neutral → Sell

Aug-25-20

Downgrade

Jefferies

Buy → Hold

Aug-24-20

Downgrade

H.C. Wainwright

Buy → Neutral

$270 → $123

Aug-19-20

Upgrade

Citigroup

Neutral → Buy

Aug-19-20

Downgrade

Barclays

Overweight → Equal Weight

Jul-10-20

Downgrade

Stifel

Buy → Hold

$298 → $193

Mar-30-20

Upgrade

Jefferies

Hold → Buy

$232

Mar-18-20

Upgrade

RBC Capital Mkts

Underperform → Sector Perform

$175 → $157

Feb-25-20

Downgrade

Cantor Fitzgerald

Overweight → Neutral

Feb-24-20

Downgrade

BofA/Merrill

Neutral → Underperform

May-16-22 09:40AM	Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year? Zacks
May-11-22 09:47AM	Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs Zacks
May-09-22 03:30PM	RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value Benzinga -5.20%
May-06-22 04:01PM	Galapagos creates new subscription right plans GlobeNewswire
May-05-22 04:01PM	Galapagos demonstrates regulatory and commercial progress in Q1 2022 GlobeNewswire
Apr-28-22 09:40AM	Has Galapagos (GLPG) Outpaced Other Medical Stocks This Year? Zacks
Apr-26-22 04:01PM	Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board GlobeNewswire
Apr-04-22 09:10AM	Strength Seen in Galapagos NV (GLPG): Can Its 5% Jump Turn into More Strength? Zacks
Mar-28-22 02:01AM	Jyseleca® approved in Japan for ulcerative colitis GlobeNewswire
Mar-24-22 04:17PM	Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders meetings GlobeNewswire
04:17PM	Correction: Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders meetings GlobeNewswire
04:01PM	Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders meetings GlobeNewswire
Mar-18-22 05:01PM	Galapagos increases share capital through subscription right exercises GlobeNewswire
Feb-24-22 04:01PM	Galapagos 2021 results set stage for future growth GlobeNewswire
Feb-03-22 04:01PM	Galapagos receives transparency notification from EcoR1 Capital GlobeNewswire
Feb-02-22 04:01PM	Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohns and Colitis Organization (ECCO) annual congress GlobeNewswire
Jan-27-22 06:07PM	Why Galapagos Trounced the Market Today Motley Fool +22.47%
10:15AM	Former J&J Scientist Stoffels to Lead Galapagos Revival Bid Bloomberg
07:50AM	Galapagos Surges On New CEO and Upgrade News Investing.com
Jan-26-22 06:01PM	Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO Reuters
05:58PM	Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO Reuters
04:40PM	Galapagos creates new subscription right plan GlobeNewswire
04:01PM	Galapagos appoints Paul Stoffels as Chief Executive Officer GlobeNewswire
Jan-18-22 04:01PM	JYSELECA® (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN GlobeNewswire
Jan-14-22 11:42AM	Is Galapagos NV (GLPG) A Good Stock To Buy? Insider Monkey +5.91%
Jan-13-22 04:01PM	Galapagos creates new subscription right plan GlobeNewswire
Jan-06-22 09:30AM	Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-24-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com
Dec-18-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com
Dec-03-21 04:01PM	Galapagos increases share capital through subscription right exercises GlobeNewswire
Nov-22-21 04:01PM	Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease GlobeNewswire
Nov-15-21 10:45AM	Jyseleca®(filgotinib) approved in the European Union for the treatment of ulcerative colitis GlobeNewswire
Nov-05-21 02:01PM	Galapagos NV (GLPG) Q3 2021 Earnings Call Transcript Motley Fool
Nov-04-21 05:01PM	Galapagos reports commercial and operational progress at Q3 financial results GlobeNewswire
Oct-25-21 09:56PM	Hedge Funds Are Piling Into Galapagos NV (GLPG) Insider Monkey
Oct-05-21 01:08PM	Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study Zacks
09:04AM	Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients Benzinga
Oct-04-21 04:01PM	Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress GlobeNewswire
07:08AM	Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease Benzinga
01:01AM	Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohns Disease GlobeNewswire
Sep-20-21 04:01PM	Galapagos increases share capital through subscription right exercises GlobeNewswire
Sep-17-21 07:15AM	GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS GlobeNewswire
Aug-31-21 09:03AM	Galapagos' Long-Serving CEO Onno Van De Stolpe To Exit After R&D Setbacks Benzinga +7.00%
Aug-30-21 04:01PM	Galapagos announces planned retirement of CEO GlobeNewswire
Aug-07-21 01:00AM	Galapagos NV (GLPG) Q2 2021 Earnings Call Transcript Motley Fool
Aug-05-21 04:01PM	Galapagos reports H1 financial results with refocused pipeline and operational progress GlobeNewswire
Jul-21-21 05:29AM	Hedge Funds Are Buying Galapagos NV (GLPG) Insider Monkey
Jul-15-21 04:20PM	Here's Why Galapagos Stock Is Falling Today Motley Fool -13.02%
10:36AM	Galapagos (GLPG) Falls on Inflammatory Study Data Readout Zacks
05:49AM	Galapagos' Another Psoriasis Candidate Shows Efficacy, Safety Profile In Mid-Stage Study Benzinga
05:45AM	Galapagos Shares Drop As SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis Patients Benzinga
Jul-14-21 04:01PM	Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study GlobeNewswire
04:01PM	Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation GlobeNewswire
Jul-10-21 05:10AM	Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis GlobeNewswire
Jun-22-21 04:01PM	Galapagos announces departure of CSO Piet Wigerinck later this year GlobeNewswire
Jun-07-21 04:01PM	Galapagos increases share capital through subscription right exercises GlobeNewswire
Jun-04-21 01:01AM	SELECTION study on filgotinib in ulcerative colitis published in The Lancet GlobeNewswire
May-27-21 04:01PM	Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress GlobeNewswire
May-18-21 04:01PM	Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting GlobeNewswire
May-07-21 08:00PM	Galapagos NV (GLPG) Q1 2021 Earnings Call Transcript Motley Fool
May-06-21 04:01PM	Galapagos refocuses pipeline and rightsizes operations GlobeNewswire
May-04-21 04:01PM	Transparency notification received from The Capital Group GlobeNewswire
Apr-30-21 04:01PM	Galapagos creates new subscription right plans GlobeNewswire
Apr-23-21 12:01AM	Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies GlobeNewswire
Apr-08-21 04:01PM	Extension of lock-up period in Gilead-Galapagos collaboration agreement GlobeNewswire
Mar-25-21 04:01PM	Publication of the annual report and invitation to the ordinary shareholders meeting GlobeNewswire
Mar-24-21 04:01PM	Galapagos appoints Bart Filius as President and Chief Operating Officer GlobeNewswire
Mar-19-21 05:01PM	Galapagos increases share capital through subscription right exercises GlobeNewswire
Mar-16-21 09:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
Mar-14-21 10:38PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG Newsfile
Mar-12-21 04:55AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
Mar-10-21 09:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
Mar-07-21 01:13PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG Newsfile
Mar-04-21 08:12AM	The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga
01:49AM	GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES GlobeNewswire
Mar-03-21 04:15PM	Transparency notification received from The Capital Group GlobeNewswire
03:20AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
Feb-23-21 06:55AM	Is Galapagos Stock a Bad-News Buy Right Now? Motley Fool
Feb-22-21 02:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG Newsfile
07:21AM	Galapagos: Upside Optionality Remains Despite Clinical Trial Failure TipRanks
Feb-20-21 06:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
Feb-19-21 06:30PM	Galapagos NV (GLPG) Q4 2020 Earnings Call Transcript Motley Fool
12:15PM	Galapagos NV to Host Earnings Call ACCESSWIRE
01:05AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
Feb-18-21 04:01PM	Pipeline and capital for growth GlobeNewswire
Feb-15-21 10:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG Newsfile
Feb-13-21 03:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
Feb-11-21 03:28PM	Gilead (GILD) & Galapagos Discontinue Development of IPF Drug Zacks
02:10PM	Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Galapagos NV (GLPG) Investigation ACCESSWIRE
11:18AM	Stocks That Hit 52-Week Lows On Thursday Benzinga
08:25AM	Gilead, Galapagos drug fails in Phase 3 clinical study MarketWatch
Feb-10-21 02:52PM	Gilead Sciences and Galapagos Shutter Their Pulmonary Fibrosis Program Motley Fool -17.76%
11:10AM	Galapagos, Gilead Sciences Pull Plug On Ziritaxestat Clinical Trials Benzinga
09:00AM	Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF Business Wire
Feb-09-21 04:01PM	The Capital Group holds 10.03% of Galapagos shares GlobeNewswire
Jan-21-21 02:08AM	NICE recommends Jyseleca® (filgotinib) on NHS in landmark decision for rheumatoid arthritis GlobeNewswire
Jan-12-21 11:54AM	Prime Minister announces new Commissioner of Nunavut CNW Group
Jan-11-21 04:01PM	Gilead holds 25.54% of Galapagos shares GlobeNewswire
Jan-06-21 09:30AM	Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-05-21 12:15PM	Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Galapagos NV (GLPG) Investigation ACCESSWIRE

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.A r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience